[go: up one dir, main page]

CL2021000175A1 - Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos - Google Patents

Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos

Info

Publication number
CL2021000175A1
CL2021000175A1 CL2021000175A CL2021000175A CL2021000175A1 CL 2021000175 A1 CL2021000175 A1 CL 2021000175A1 CL 2021000175 A CL2021000175 A CL 2021000175A CL 2021000175 A CL2021000175 A CL 2021000175A CL 2021000175 A1 CL2021000175 A1 CL 2021000175A1
Authority
CL
Chile
Prior art keywords
preventing
same
pharmaceutical compositions
cancers including
treating cancers
Prior art date
Application number
CL2021000175A
Other languages
English (en)
Inventor
Jae Yul Choi
In Hwan Bae
Ji Sook Kim
Seok Jong Kang
Young Gil Ahn
Kwee Hyun Suh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2021000175A1 publication Critical patent/CL2021000175A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto de pirimidina representado por la Fórmula 1, un método para preparar el compuesto, y un uso farmacéutico del compuesto para la prevención o el tratamiento del cáncer.
CL2021000175A 2018-07-25 2021-01-22 Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos CL2021000175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180086768A KR101954370B1 (ko) 2018-07-25 2018-07-25 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
CL2021000175A1 true CL2021000175A1 (es) 2021-07-02

Family

ID=65760263

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000175A CL2021000175A1 (es) 2018-07-25 2021-01-22 Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos

Country Status (17)

Country Link
US (2) US11292786B2 (es)
EP (1) EP3810601A4 (es)
JP (1) JP6806931B2 (es)
KR (1) KR101954370B1 (es)
CN (2) CN116693506B (es)
AR (1) AR119657A1 (es)
BR (1) BR112021001122A2 (es)
CA (1) CA3106961A1 (es)
CL (1) CL2021000175A1 (es)
DO (1) DOP2021000017A (es)
MX (1) MX2021000941A (es)
PE (1) PE20210373A1 (es)
PH (1) PH12021550124A1 (es)
SG (1) SG11202100076RA (es)
TW (1) TWI839363B (es)
WO (1) WO2020022600A1 (es)
ZA (1) ZA202100485B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7577672B2 (ja) 2019-02-22 2024-11-05 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
CN114650823A (zh) * 2019-06-27 2022-06-21 韩美药品株式会社 用于治疗急性髓系白血病的含有flt3抑制剂和化疗剂的药物组合物
WO2021066443A1 (ko) * 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
EP4241773A4 (en) * 2020-11-05 2024-10-16 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA WITH FLT3 INHIBITOR
MX2023009954A (es) * 2021-02-26 2023-11-09 Tyra Biosciences Inc Compuestos de aminopirimidina y métodos de uso de estos.
WO2022216097A1 (ko) * 2021-04-08 2022-10-13 주식회사 스탠다임 신규한 lrrk2 억제제
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20230056331A (ko) * 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
EP4525873A1 (en) 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
CA2702126A1 (en) * 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
JP2012533553A (ja) * 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
PL2585470T3 (pl) * 2010-06-23 2017-07-31 Hanmi Science Co., Ltd. Nowe sprzężone pochodne pirymidyny do hamowania aktywności kinazy tyrozynowej
TW201219383A (en) * 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
DK3126352T3 (en) * 2014-04-04 2019-01-21 Syros Pharmaceuticals Inc CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7)
AU2017289315B2 (en) 2016-06-30 2021-04-01 Janssen Pharmaceutica Nv Heteroaromatic derivatives as NIK inhibitors
PL3514153T3 (pl) * 2017-01-26 2022-01-17 Hanmi Pharm. Co., Ltd. Związek pirymidynowy i jego zastosowanie farmaceutyczne

Also Published As

Publication number Publication date
US20230002358A1 (en) 2023-01-05
CN112469715B (zh) 2024-06-11
US20200255410A1 (en) 2020-08-13
JP2020527128A (ja) 2020-09-03
TWI839363B (zh) 2024-04-21
DOP2021000017A (es) 2021-04-15
TW202014417A (zh) 2020-04-16
CN116693506B (zh) 2024-11-26
PE20210373A1 (es) 2021-02-26
PH12021550124A1 (en) 2021-09-27
JP6806931B2 (ja) 2021-01-06
ZA202100485B (en) 2023-11-29
MX2021000941A (es) 2021-03-09
BR112021001122A2 (pt) 2021-04-13
CA3106961A1 (en) 2020-01-30
SG11202100076RA (en) 2021-02-25
KR101954370B1 (ko) 2019-03-05
EP3810601A1 (en) 2021-04-28
WO2020022600A1 (en) 2020-01-30
CN116693506A (zh) 2023-09-05
US11292786B2 (en) 2022-04-05
EP3810601A4 (en) 2022-04-20
AR119657A1 (es) 2022-01-05
NZ772028A (en) 2024-09-27
CN112469715A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
AR120700A1 (es) Inhibidores de kras g12c
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
AR122786A2 (es) Inhibidores de kras g12c y métodos para su uso
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
CO2022001453A2 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2020011868A (es) Inhibidores de los receptores erbb.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
MX378509B (es) Compuesto de pirimidina y su uso farmaceutico.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
CY1121885T1 (el) Αντι-ογκικες ενωσεις
MX2024007360A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
MX389163B (es) Inhibidores de la isocitrato deshidrogenasa mutante y sus composiciones y metodos.
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores